Tridek-One

Tridek-one email format

Verified email-pattern data for Tridek-One is currently limited. You can still use the company insights and contact sections below.
Tridek-One is a spin-off from Inserm that develops first-in-class therapeutic agonistic monoclonal antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases. The company primarily focuses on the research and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance. Anti-CD31 agonistic mAbs have the potential to provide targeted immunomodulatory activity with a favorable safety profile in diseases with high unmet clinical need. Tridek-One has initiated a discovery program which targets another ITIM receptor, fully leveraging its understanding of inhibitory checkpoint receptor modulation and agonistic monoclonal antibodies engineering. Our company is financed by leading European investors and led by an experienced management team.

Company Details

Employees
14
Founded
-
Address
4, Rue Thénard, Paris,île-De-France 75005,france
Industry
Biotechnology Research
HQ
Paris, Île-de-France
Looking for a particular Tridek-One employee's phone or email?

Tridek-One Questions

Explore related pages

Related company profiles:

Top Tridek-One Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant